WilmerHale Reps Infinity Pharma in $28M Licensing Agreement with Verastem

WilmerHale Reps Infinity Pharma in $28M Licensing Agreement with Verastem

Firm News

Verastem, Inc. and Infinity Pharmaceuticals, Inc. announced that the companies entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialize Infinity's oncology product candidate duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being investigated for the treatment of hematologic cancers.

Verastem will pay Infinity up to $28 million in milestones, with positive data from DUO®, a Phase 3, randomized monotherapy study of duvelisib in patients with relapsed/refractory CLL, triggering the first milestone payment, and royalties on net sales.

The WilmerHale deal team was led by Partners Belinda Juran and Steven Singer and included Associate Alex Civetta.

Read Infinity's press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.